Comparative Pharmacology
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE HIVES versus PROMETHAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE HIVES versus PROMETHAZINE DM.
FEXOFENADINE HYDROCHLORIDE HIVES vs PROMETHAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine hydrochloride is a selective peripheral H1-receptor antagonist. It blocks the action of histamine at the H1 receptor, preventing histamine-mediated symptoms such as itching, sneezing, rhinorrhea, and urticaria.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
60 mg orally twice daily or 180 mg orally once daily
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 14.4 hours (range 11–17 hours) in healthy adults. Clinically, this supports twice-daily dosing for symptomatic relief.
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Approximately 95% of the dose is excreted unchanged in feces (80%) and urine (15%). Fexofenadine undergoes minimal hepatic metabolism (<5%).
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic